Resilient Biotics - About the company
Resilient Biotics is a series A company based in El Cerrito (United States), founded in 2016 by Christopher Belnap. It operates as a Developer of microbiome therapeutics to treat complex infectious diseases. Resilient Biotics has raised $11M in funding from investors like Illumina, Berkeley Catalyst Fund and Fulcrum Global Capital. The company has 754 active competitors, including 271 funded and 173 that have exited. Its top competitors include companies like Alnylam, Spark Therapeutics and Spero Therapeutics.
Company Details
Developer of microbiome therapeutics to treat complex infectious diseases. The company uses genomic technologies and intelligent analytics to develop antibiotic replacements for complex infectious diseases. The company is in stealth mode and is being incubated in the Illumina Accelerator.
- Website
- resilientbiotics.com
- Social
- Email ID
- *****@resilientbiotics.com
Key Metrics
Founded Year
2016
Location
El Cerrito, United States
Stage
Series A
Total Funding
$11M in 3 rounds
Latest Funding Round
Ranked
228th among 754 active competitors
Employee Count
10 as on May 31, 2026
Sign up to download Resilient Biotics' company profile
Resilient Biotics's funding and investors
Resilient Biotics has raised a total funding of $11M over 3 rounds. Its first funding round was on Feb 12, 2017. Resilient Biotics has 8 institutional investors.
Here is the list of recent funding rounds of Resilient Biotics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Aug 16, 2022 | 2348914 | Series A | 3994866 | 1856464 | 5548956 | 6387597 |
Dec 09, 2020 | 4735953 | Series A | 4356457 | 1871062 | 9372694 | |
Feb 12, 2017 | 6078129 | Seed | 4621689 | 4202660 | 5550386 |
Access funding benchmarks and valuations. Sign up today!View details of Resilient Biotics's funding rounds and investors
Resilient Biotics' founders and board of directors
Founder? Claim ProfileThe founders of Resilient Biotics is Christopher Belnap.
Here are the details of Resilient Biotics' key team members:
- Christopher Belnap: Co-Founder of Resilient Biotics.
View details of Resilient Biotics's Founder profiles and Board Members
Resilient Biotics' employee count trend
Resilient Biotics has 10 employees as of May 26. Here is Resilient Biotics's employee count trend over the years:
Uncover Resilient Biotics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Resilient Biotics's Competitors and alternates
Top competitors of Resilient Biotics include Alnylam, Spark Therapeutics and Spero Therapeutics. Here is the list of Top 10 competitors of Resilient Biotics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Alnylam 2002, Cambridge (United States), Public | Developer of RNA interference-based therapeutics for multiple disorders | $17M | 79/100 | |
2nd | Spark Therapeutics 2013, Philadelphia (United States), Acquired | Developer of gene therapy for rare diseases | $82.8M | 73/100 | |
3rd | Spero Therapeutics 2013, Cambridge (United States), Public | Developer of therapeutics for drug-resistant bacterial infections | $115M | 71/100 | |
4th |  Strand Therapeutics 2017, Cambridge (United States), Series B | Provider of platform to deliver mRNA therapeutics for multi functional treatments | $256M | 70/100 | |
5th |  Forge Biologics 2020, Columbus (United States), Acquired | Developer of gene therapeutic solutions for treating multiple diseases | $330M | 70/100 | |
6th |  Insitro 2018, San Francisco (United States), Series C | Developer of machine learning platform for drug discovery and development | $643M | 70/100 | |
7th | _1560516450043.png?devicePixelRatio=2&height=30&width=30){kind=logo} Passage Bio 2017, Philadelphia (United States), Public | Developer of gene therapies for CNS rare diseases | $226M | 69/100 | |
8th | Ultragenyx 2010, Novato (United States), Acquired | Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases | $135M | 69/100 | |
9th |  Generation Bio 2016, Cambridge (United States), Acquired | Developer of gene therapies for rare liver and eye diseases | $236M | 69/100 | |
10th | ElevateBio 2018, Cambridge (United States), Series D | Provider of transnational research for portfolio of cell and gene therapy | $1.25B | 68/100 | |
228th | Resilient Biotics 2016, El Cerrito (United States), Series A | Developer of microbiome therapeutics to treat complex infectious diseases | $11M | 44/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Resilient Biotics's competitors? Click here to see the top ones
Resilient Biotics's Investments and acquisitions
Resilient Biotics has made no investments or acquisitions yet.
Reports related to Resilient Biotics
Here is the latest report on Resilient Biotics's geography:
News related to Resilient Biotics
•
•
•
Illumina Adds Three Startups to Accelerator ProgramSan Diego Business Journal•Feb 12, 2017•Illumina, Resilient Biotics
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Resilient Biotics
Explore our recently published companies
- Imagicle - Massarosa based, 2010 founded, Unfunded company
- iDO Devices - Noida based, 2025 founded, Seed company
- Onviant - 2018 founded, Unfunded company
- Apprentice - Tel Aviv-Yafo based, 2023 founded, Funding Raised company
- GeoHeim - Seoul based, 2020 founded, Funding Raised company
- House of ROI - New York City based, 2026 founded, Unfunded company
